Concentrations and effects of buspirone are considerably reduced by rifampicin

British Journal of Clinical Pharmacology

Volumn 45, Issue 4, 1998, Pages 381-385

  Lamberg, T S ^a   Kivisto K T ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Buspirone; Interaction; Pharmacokinetics; Rifampicin

Indexed keywords

BUSPIRONE; CARBAMAZEPINE; CYTOCHROME P450; PHENYTOIN; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; BUSPIRONE; FEMALE; HUMANS; MALE; PLACEBOS; RIFAMPIN;

EID: 0031933827     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00698.x     Document Type: Article

References (18)

1. Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114-129.
2. Bond AJ, Lader MH. Comparative effects of diazepam and buspirone on subjective feelings, psychological tests and the EEG. Int Pharmacopsychiatry 1981; 16: 212-220.
3. Bond A, Lader M, Shrotnya R. Comparative effects of a repeated dose regime of diazcpam and buspirone on subjective ratings, psychological tests and the EEG. Eur J Clin Pharmacol 1983; 24: 463-467.
4. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994; 56: 100-111.
5. 14C-buspirone HCl after intravenous and oral dosing in man. Clin Pharmacol Ther 1985; 37: 210.
6. Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997; 62: 348-354.
7. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878.
8. Venkatesan K. Pharmacokinetic drug interactions with nfampicin. Clin Pharmacokinet 1992; 22: 47-65.
9. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59: 7-13.
10. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking nfampin. Clin Pharmacol Ther 1997; 61: 8-14.
11. Gaillard Y, Gay-Montchamp JP, Ollagnier M. Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron capture and nitrogen-phosphorous detection after solid-phase extraction. J Chromatogr 1993; 622: 197-208.
12. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampicin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
13. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampicin. Hepatology 1996; 24: 796-801.
14. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80(Suppl. 3B): 41-51.
15. Jajoo HK, Mayol RF, LaBudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989; 17: 634-640.
16. Jajoo HK, Blair IA, Klunk LJ, Mayol RF. In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. Xenobiotica 1990; 20: 779-786.
17. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996; 42: 387-389.
18. Backman JT, Olkkola KT, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253-257.